2007 February 17, Andrew Pollack, “Growth Drug Is Caught Up in Patent Fight”, in New York Times[1]:
Both sell drugs that were approved in 2005 to treat extremely short children who are deficient in a hormone called insulinlike growth factor one, or IGF-1.